Aardvark Therapeutics今日宣布，已向美国食品药品监督管理局（FDA）提交了其主打候选药物ARD-101的修订临床试验方案，并已获得机构审查委员会（IRB）的批准。此项修订旨在扩大针对普瑞德-威利综合征（PWS）的III期临床研究的受试者资格范围。
Aardvark Therapeutics今日宣布，已向美国食品药品监督管理局（FDA）提交了其主打候选药物ARD-101的修订临床试验方案，并已获得机构审查委员会（IRB）的批准。此项修订旨在扩大针对普瑞德-威利综合征（PWS）的III期临床研究的受试者资格范围。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.